title:
A Phase 1/2 Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of the Oral EGFR/HER2 Inhibitor TAK-788 (AP32788) in Non-Small Cell Lung Cancer

 Étude de phase 1/2 évaluant la tolérance, la pharmacocinétique et l’activité antitumorale de l’inhibiteur oral de EGFR/HER2 TAK-788 (AP32788) dans les cancers du poumon non à petites cellules

lead_sponsor: Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited


title: A Randomized, Controlled, Open-label, Phase 2 Study of Cemiplimab as a Single Agent and in Combination with RP1 in Patients with Advanced Cutaneous Squamous Cell Carcinoma

source: euctr

lead_sponsor: Replimune, Inc.

study_type: Interventional

status: Ongoing

lead_sponsor_type: industriel

status_simplified: Ongoing


title: A Phase II Study of Pembrolizumab Monotherapy in Third-line Previously Treated Subjects with Advanced/Metastatic Adenocarcinoma or Squamous Cell Carcinoma of the Esophagus or Advanced/Metastatic Siewert Type I Adenocarcinoma of the Esophagogastric Junction (KEYNOTE -180)

acronym: Study of Pembrolizumab in Previously Treated Subjects with Advanced/Metastatic Adenocarcinoma

lead_sponsor: Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.

status: Completed

status_simplified: Completed


title: A Phase 1b/2 Study of FT-2102 in Patients with Advanced Solid Tumors and Gliomas with an IDH1 Mutation

lead_sponsor: FORMA Therapeutics, Inc.


title:
A Phase lllb, open-label, single-arm, single-dose, multicenter study to evaluate the safety, tolerability and efficacy of gene replacement therapy with intravenous OAV101 (AVXS-101) in pediatric patients with spinal muscular atrophy (SMA)

 Etude de phase IIIb, multicentrique, en ouvert, à un seul bras, évaluant la sécurité d’emploi, la tolérance, et l’efficacité d’une dose unique de thérapie génique par OAV101 (AVXS-101), administrée par voie intraveineuse, chez des patients pédiatriques atteints d’amyotrophie spinale

acronym: SMART

lead_sponsor: Novartis Pharma AG


title: Phase 1b/2, Multicenter, Open-label Study of Carfilzomib, Carboplatin, and Etoposide in Subjects with Previously Untreated Extensive-stage Small-cell Lung Cancer

lead_sponsor: Onyx Therapeutics, Inc.


title:
Efficacy of eltrombopag plus lenalidomide combination therapy in patients with IPSS low and intermediate-risk myelodysplastic syndrome with isolated del5q: a multicenter, randomized, double-blind, placebo controlled study

 Etude clinique de la phase II multicentrique randomisée en double-aveugle testant l’efficacité de l’association d’Eltrombopag et de Lénalidomide contre placebo dans les SMD d’IPSS faible ou intermédiaire-1 avec del5q isolée

acronym:
QOL-ONE Rev2MDS

 QOL-ONE Rev2MDS

lead_sponsor: ASSOCIAZIONE QOL-ONE


title: A Randomised, Double-Blind, Placebo-Controlled Phase 3 Clinical Trial to Assess the Efficacy and Safety of Lebrikizumab in Combination With Topical Corticosteroids in Adult and Adolescent Patients With Moderate-To-Severe Atopic Dermatitis That Are Not Adequately Controlled With Cyclosporine or For Whom Cyclosporine is Not Medically Advisable

acronym: ADvantage

lead_sponsor: Almirall, S.A.

status_simplified: Unknown


title:
A Phase 3/4, Multinational, Multicenter, Double-Blind, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of Aramchol in Subjects with Nonalcoholic Steatohepatitis (NASH)
 The ARMOR Study

lead_sponsor: Galmed Research and Development, Ltd.


title: Phase II Study of Combination Bortezomib, Dexamethasone, and Rituximab in previously untreated Patients with Waldenstrom’s Macroglobulinemia: A multicenter Trial of the European Myeloma Network

acronym: protocole BDR

lead_sponsor: Centre Hospitalier de Lens

lead_sponsor_type: academique


title: A Phase 2, Double-blind, Randomized, Placebo-controlled Multicenter Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of JBT-101 in Cystic Fibrosis

lead_sponsor: Corbus Pharmaceuticals, Inc.


title: Randomized, double-blind, placebo controlled, multi-centre, superiority phase II study to evaluate the safety, pharmacokinetic, efficacy of gabapentin liquid formulation as add-on to morphine in children from 3 months to less than 18 years of age experiencing severe chronic neuropathic or mixed pain.

acronym: Efficacy and safety study to compare gabapentin as add on to morphine in paediatric patients

lead_sponsor: PHARM – Pharmaceutical Research Management srl


title: Pulmonary vein isolation with versus without continued antiarrhythmic drug treatment in subjects with persistent atrial fibrillation: a prospective multi-centre randomized controlled clinical study (POWDER-AF2 study)

lead_sponsor: AZ Sint-Jan Brugge-Oostende AV


title: A Single-Arm Study to Provide Boceprevir Treatment in Subjects with Chronic Hepatitis C Genotype 1 Deemed Nonresponders to Peginterferon/Ribavirin in Previous Schering-Plough Boceprevir Studies.

lead_sponsor: Schering-Plough Research Institute, A Division of Schering Corporation


title: A MULTICENTER RANDOMIZED PLACEBO-CONTROLLED PHASE 3 STUDY ON THE SAFETY AND EFFICACY OF DEFLAZACORT (EMFLAZA®) IN SUBJECTS WITH LIMB-GIRDLE MUSCULAR DYSTROPHY 2I (LGMD2I

lead_sponsor: PTC Therapeutics, Inc.


title: A prospective, multicentre, open-label, randomised, uncontrolled, phase 1/2 study to evaluate efficacy and safety of masitinib in combination with etoposide, or masitinib in combination with irinotecan in patients with advanced hepatocellular carcinoma and who relapsed after a first line therapy with sorafenib.

lead_sponsor: AB Science


title: A MULTICENTER, OPEN-LABEL, MULTIPLE ASCENDING DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND EFFICACY OF SUBCUTANEOUS AND/OR INTRAVENOUS PF-06741086 IN SUBJECTS WITH SEVERE HEMOPHILIA

lead_sponsor: Pfizer Inc., 235 East 42nd Street, New York, NY 10017


title:
A Long-term Follow-up Study for Cardiac Safety in the Patients with HER2 Positive Early or Locally Advanced Breast Cancer Who Have Completed the SB3-G31-BC

 Étude de suivi à long terme de l‘innocuité sur le plan cardiaque chez les patientes atteintes d’un cancer du sein HER2 positif de stade précoce ou localement avancé ayant terminé l’étude SB3-G31-BC

lead_sponsor: Samsung Bioepis Co., Ltd.


title: A Multicenter, Double-Blind, Active-Controlled, Parallel Group Study to Examine the Safety, Tolerability and Efficacy of Oral MK-0974 for the Long Term Treatment of Acute Migraine With or Without Aura

lead_sponsor: Laboratoires Merck Sharp & Dohme - Chibret


title: Proof of Concept study of the efficacy and tolerability of a 4-week treatment with F13640 in patients in whom the adaptation of opioid therapy of cancer pain has failed. A prospective, multinational, multicentre, randomised, double-blind, placebo-controlled study.

lead_sponsor: PIERRE FABRE MEDICAMENT

status: Prematurely Ended


title: A multi-center open label extension study of HGT-1111 (Recombinant Human Arylsulfatase A or rhASA) treatment in patients with Late Infantile Metachromatic Leukodystrophy (MLD)

lead_sponsor: Shire Human Genetic Therapies Inc


title: A randomised, double-blind, placebo-controlled, multi national, Phase III study of the efficacy and safety of 300 IR sublingual immunotherapy (SLIT), starting 2 months before the grass pollen season, administered as allergen based tablets once daily to patients suffering from grass pollen rhinoconjunctivitis (with or without asthma)

lead_sponsor: Stallergenes S.A.


title: Prospective, open-label, multicenter, international study of mifepristone for symptomatic treatment of Cushing's syndrome caused by ectopic Adrenal Corticotrophin Hormone (ACTH) secretion.

acronym: HRA052015 in EAS

lead_sponsor: Laboratoire HRA Pharma


title: A Phase IIa, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of Odanacatib (MK-0822) on Bone Mineral Density (BMD) and Overall Safety in the Treatment of Osteoporosis in Postmenopausal Women Previously Treated with Alendronate

acronym: Odanacatib Study in Patients Previously Treated with Alendronate

lead_sponsor: Merck & Co. Inc


title: A randomised open-label study comparing the safety and efficacy of three different combination antiretroviral regimens as initial therapy for HIV infection.

acronym: Altair

lead_sponsor: University of New South Wales


title: A randomised, open-label, multi-centre, 2-stage, parallel group study to assess the efficacy, safety and tolerability of AZD1152 alone and in combination with low dose cytosine arabinoside (LDAC) in comparison with LDAC alone in patients aged ≥ 60 with newly diagnosed acute myeloid leukaemia (AML) who are considered unsuitable to receive intensive induction chemotherapy regimens

lead_sponsor: AstraZeneca AB


title: A Phase I/II, Open-Label, Multicenter, Two-Arm, Feasibility Study of Pazopanib, Carboplatin, and Paclitaxel in Women with Newly Diagnosed, Previously Untreated, Gynaecological Tumors

lead_sponsor: GlaxoSmithkline Research & Development Limited


title: A Phase IIa Randomized, Double-Blind, Parallel-Group, Placebo and Active-Controlled, Clinical Trial to Study the Efficacy and Safety of MK-0974 Co-administered with Ibuprofen or Acetaminophen in Patients with Migraine With or Without Aura

lead_sponsor: Laboratoires Merck Sharp & Dohme-Chibret


title: A phase III randomized, double-blind, double dummy, placebo controlled, multicenter, 4 treatments, 3 period incomplete block crossover study to assess the effect on FEV1 of indacaterol 300 µg o.d. dosed in the evening in patients with moderate to severe chronic obstructive pulmonary disease (COPD) with salmeterol as active control

lead_sponsor: Novartis Pharma Services AG


title: Etude ATOLL . Etude internationale, multicentrique, visant à comparer l'utilisation de l'enoxaparine IV versus héparine standard IV chez les sujets présentant un infarctus du myocarde aigu et nécessitant l'intervention coronarienne  percutanée primaire

acronym: ATOLL

lead_sponsor: ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)


title: Adults adminstered Venlafaxine and Eszopiclone Response to Treatment (AVERT): A 31-Week, Efficacy, Safety and Tolerability Study of Eszopiclone 3 mg Co-administered with Venlafaxine in Subjects with Major Depressive Disorder (MDD) and Co-existing Insomnia

lead_sponsor: Sepracor NV in care of Sepracor Inc.


title: Efficacy and safety assessment of intracameral T2380  (Fixed combination of lidocaïne, phenylephrine and tropicamide)  for anaesthesia and mydriasis in phacoemulsification cataract surgery

lead_sponsor: Laboratoires Théa


title: A Multicentre, Interventional, Non-randomized, Open-label, Single-group Phase III Study to evaluate Plasma-Derived Antihaemophilic Factor/von Willebrand Factor Concentrate (Biostate®) for Immune Tolerance Induction in Male Paediatric Subjects with Haemophilia A (≤2%) who have Developed High-titre Antibodies to Factor VIII (Factor VIII Inhibitors)

acronym: SWIFT-ITI

lead_sponsor: CSL Behring GmbH


title: A phase 2B, randomised, double-blind, placebo-controlled, parallel group, multi-centre study to investigate the efficacy, mechanism of action, pharmacokinetics, safety and tolerability of the mGluR5 negative allosteric modulator ADX10059 as monotherapy in patients with Gastroesophageal Reflux Disease (GERD)

lead_sponsor: Addex Pharma SA


title: An open-label, single treatment, safety and efficacy, long-term study of deferiprone in subjects with Friedreich's ataxia.

acronym: Not applicable

lead_sponsor: ApoPharma Incorporated


title: Multicenter, parallel, controlled, randomized, single blind clinical evaluation of a new low sodium peritoneal dialysis solution on patients with hypertension treated with  continous ambulatory or automated peritoneal dialysis.

acronym: PDOne

lead_sponsor: Gambro Lundia AB


title: A RANDOMIZED, PARTIALLY-BLINDED, MULTI-CENTER, ACTIVE-CONTROLLED, DOSE RANGING STUDY ASSESSING THE SAFETY, EFFICACY, AND PHARMACODYNAMICS OF THE REG1 ANTICOAGULATION SYSTEM COMPARED TO UNFRACTIONATED HEPARIN OR LOW MOLECULAR HEPARIN IN SUBJECTS WITH ACUTE CORONARY SYNDROME

acronym: RADAR

lead_sponsor: Regado Biosciences, Inc


title: A randomised, multicentre, double-blind, placebo-controlled, crossover trial determining the efficacy of dry powder mannitol in improving lung function in subjects with Cystic Fibrosis aged six to seventeen years

acronym: DPM-CF-204 mannitol in CF aged 6-17 years

lead_sponsor: Pharmaxis Ltd.


title: A Multicenter, Randomized, Double-blind Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Patients with Major Depressive Disorder.

acronym: ACES 263

lead_sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc


title: Open-label, non-controlled, multicenter long-term study to investigate the safety and efficacy of Xeomin® (incobotulinumtoxin A, NT 201) for the treatment of spasticity of the lower limb(s) or of combined spasticity of upper and lower limb in children and adolescents (age 2 - 17 years) with cerebral palsy

lead_sponsor: Merz Pharmaceuticals GmbH


title: A phase Ib/II, open-label study of LJM716 in combination with BYL719 compared to taxane or irinotecan in patients with previously treated esophageal squamous cell carcinoma


title: A 28 week extension to a 24 week multi-center, randomized, double-blind clinical trial to evaluate the safety and tolerability of vildagliptin (50 mg qd) versus placebo in patients with type 2 diabetes and moderate or severe renal insufficiency

lead_sponsor: Novartis Services AG


title: Phase I-II study of F14512 in combination with cytarabine in patients 60 years old and older with acute myeloid leukemia.

lead_sponsor: Pierre Fabre Medicament


title:
TIGER-1:  A Randomized, Open-label, Phase 2/3 Study of CO-1686 or Erlotinib as First-Line Treatment of Patients with EGFR-Mutant Advanced/Metastatic  Non-Small Cell Lung Cancer (NSCLC)

 TIGER-1 : Étude randomisée, ouverte, de phase 2/3 visant à évaluer le CO-1686 ou l’Erlotinib comme traitement de première ligne chez des patients atteints d’un cancer du poumon non à petites cellules (CPNPC) muté EGFR à un stade avancé/métastatique

lead_sponsor: Clovis Oncology, Inc.


title: A multi-center, randomized, double-blind, placebo-controlled Phase IIa trial to compare the safety of ABX464 given at a fixed dose to placebo in fully controlled HIV infected patients treated with boosted protease inhibitor treatment (darunavir/ritonavir or darunavir/cobicistat).

lead_sponsor: Abivax


title: CLINICAL EFFICACY AND SAFETY OF TAZAROTENE CREAM 0.05% IN THE INITIAL AND MAINTENANCE THERAPIES OF LAMELLAR ICHTHYOSIS (LI)

lead_sponsor: Orfagen


title: A Long Term Follow-up Study of AMG0001 in Subjects with Critical Limb Ischemia

lead_sponsor: AnGes Inc.


title:
A Phase 1b Study Followed by an Open label, Parallel, Randomized Phase 2 Study Evaluating the Safety, Tolerability and Efficacy of GS-5829 in Combination with Exemestane or Fulvestrant Comparing
 with Exemestane or Fulvestrant Alone in Subjects with Advanced Estrogen Receptor Positive HER2- Breast Cancer

lead_sponsor: Gilead Sciences, Inc.


title: Safety and pharmacokinetics of ODM-207 in patients with selected advanced solid tumours: an open-label, non-randomised, uncontrolled, multicentre, first-in-human study  with cohort expansion

acronym: BETIDES

lead_sponsor: Orion Corporation Orion Pharma


title: A Phase 2 Study of Nivolumab in Combination with Either Rucaparib, Docetaxel, or Enzalutamide in Men with Castration-resistant Metastatic Prostate Cancer

acronym: CheckMate 9KD: CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 9KD

lead_sponsor: Bristol-Myers Squibb International Corporation


title:
Multicenter Phase II Safety and Preliminary Efficacy Study of 2 dose regimens of HepaStem in Patients with Acute on Chronic Liver Failure.

 Etude Clinique multicentrique de phase II visant à évaluer la sécurité et l’efficacité préliminaire de 2 doses d’HepaStem chez des patients souffrant d’insuffisance hépatique aiguë sur une maladie chronique du foie.

lead_sponsor: Promethera Biosciences


title: A multicenter, open-label, sponsor-blinded, randomized, active-controlled, parallel group, pivotal study to evaluate the efficacy, safety, and tolerability of murepavadin given with ertapenem versus an anti-pseudomonal-β lactam-based antibiotic in adult subjects with nosocomial pneumonia suspected or confirmed to be due to Pseudomonas aeruginosa.

lead_sponsor: Polyphor Ltd.


title: An Open-Label, Single-Arm, Multicenter Study of Intracerebral Administration of Adeno-Associated Viral Vectors Serotype rh10 Carrying the Human N-sulfoglucosamine sulfohydrolase (SGSH) cDNA for the Treatment of Mucopolysaccharidosis Type IIIA

lead_sponsor: Lysogene SA


title: Adaptive design phase 2 to 3, randomized, double- blind, multicenter, to evaluate the safety, efficacy, pharmacokinetics and pharmacodynamics of BIO101 in the prevention of the respiratory deterioration in hospitalized patients with COVID-19 pneumonia (severe stage)

lead_sponsor: Biophytis S.A.


title: A Randomised Active-controlled Study to Compare Efficacy and Safety of Inhaled Isoflurane Delivered by the AnaConDa-S (Anaesthetic Conserving Device) to Intravenous Midazolam for Sedation in Mechanically Ventilated Paediatric Patients 3 to 17 (Less than 18) Years Old

acronym: IsoCOMFORT study

lead_sponsor: Sedana Medical AB


title: A Phase III Randomized, Double-blind, Placebo-controlled, Multi-center Study in Adults to Determine the Safety and Efficacy of AZD7442, a Combination Product of Two Monoclonal Antibodies (AZD8895 and AZD1061), for Pre-exposure Prophylaxis of COVID-19

acronym: Phase 3 Double-blind study of AZD7442 or Placebo for Pre-exposure Prophylaxis of COVID-19 in Adults

lead_sponsor: AstraZeneca AB


title:
A Phase III, Open-label, Randomized Study of Osimertinib with or without Platinum Plus Pemetrexed Chemotherapy, as First-line Treatment in Patients with Epidermal Growth Factor Receptor (EGFR) Mutation Positive, Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLAURA2)

 Étude de phase III, en ouvert, randomisée, évaluant l’osimertinib avec ou sans chimiothérapie à base de platine associée au pémétrexed, en traitement de première ligne chez les patients atteints d’un cancer du poumon non à petites cellules avec mutation du récepteur du facteur épidermique de croissance (EGFR) localement avancé ou métastatique (FLAURA2)


title: A Phase 3 Clinical Study to Evaluate the Efficacy and Safety of the Combination Regimen of MK-3682B (Grazoprevir/Ruzasvir/Uprifosbuvir) in Participants with Chronic Hepatitis C Virus Genotype 3 Infection

acronym: MK-3682B in Hepatitis C Virus (HCV) Genotype 3 (GT3) participants

lead_sponsor: Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.


title: A Phase 3, Multicenter, Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Plazomicin Compared with Colistin in Patients with Infection due to Carbapenem-Resistant Enterobacteriaceae (CRE)

lead_sponsor: Achaogen, Inc.


title:
Additive Effect of Twice Daily Brinzolamide 1% /Brimonidine 0.2% Fixed Dose Combination as an Adjunctive Therapy to a Prostaglandin Analogue

 Effet additif d'une administration deux fois par jour d'une association fixe de brinzolamide 1%/brimonidine 0.2% associé à un traitement par un analogue de la prostaglandine.

acronym: Simbrinza BID as an Adjunctive to Prostaglandin Analogue (PGA)

lead_sponsor: Alcon Research, Ltd.


title: An Observational Follow-Up Study of Pediatric Patients Who Participated in a Previous Respiratory Syncytial Virus (RSV)-Induced Bronchiolitis Study of Montelukast

lead_sponsor: Laboratoires Merck Sharp & Dohme - Chibret


title:
International, multicentre, efficacy and safety study of I10E in the
 maintenance treatment of patients with Chronic Inflammatory
 Demyelinating Polyradiculoneuropathy: Extension of PRISM study
 I10E-1302

acronym: PRISM 2

lead_sponsor: LFB BIOTECHNOLOGIES


title: A 24-WEEK MULTICENTRE, RANDOMISED, DOUBLE BLIND, CONTROLLED, PARALLEL GROUP NON-INFERIORITY STUDY TO ASSESS THE EFFICACY AND SAFETY OF OLMESARTAN MEDOXOMIL VERSUS CANDESARTAN CILEXETIL IN PATIENTS WITH SYMPTOMATIC HEART FAILURE (NYHA II-IV)

acronym: OLMEBNP

lead_sponsor: DAIICHI SANKYO EUROPE GmbH


title: A twenty-four week, open-label, non-comparative, multicenter study to assess the efficacy and tolerability of an aliskiren-based treatment algorithm in patients with mild to moderate hypertension.

lead_sponsor: Novartis Pharma Services AG


title:
An International, Multicenter, Open-label, Long Term Extension Study Evaluating the Safety of Diacerein 1% Ointment Topical Formulation in Subjects with Epidermolysis Bullosa Simplex (EBS)

 Étude internationale d'extension à long terme, multicentrique, en ouvert, évaluant l’innocuité de la pommade à la diacéréine 1 % en application locale chez les patients atteints d’épidermolyse bulleuse simple (EBS)

lead_sponsor: Castle Creek Pharmaceuticals, LLC


title: AN OPEN-LABEL, MULTICENTER, MULTIPLE-DOSE PHARMACOKINETIC AND 48-WEEK SAFETY AND EFFICACY TRIAL OF MARAVIROC IN COMBINATION WITH OPTIMIZED BACKGROUND THERAPY FOR THE TREATMENT OF ANTIRETROVIRAL-EXPERIENCED CCR5-TROPIC HIV-1 INFECTED CHILDREN 2-18 YEARS OF AGE

lead_sponsor: Pfizer Inc, 235 East 42nd Street, New York, NY 10017


title: A Randomized, Double-blind, Multicenter Phase III Study of Brivanib versus Placebo as Adjuvant Therapy to Trans-Arterial Chemo-Embolization (TACE) in Patients with Unresectable Hepatocellular Carcinoma: The BRISK TA Study

acronym: The BRISK TA Study

lead_sponsor: Bristol Myers Squibb International Corporation


title: A multi-center, randomized, double-blind clinical trial to evaluate the safety and tolerability of 24 weeks treatment with vildagliptin (50 mg qd or 100 mg qd) versus placebo in patients with type 2 diabetes and moderate renal insufficiency


title: A multicentre, randomised, double-blind, placebo-controlled, parallel group, dose ranging study to determine the effect of mepolizumab on exacerbation rates in subjects with severe uncontrolled refractory asthma.

lead_sponsor: GlaxoSmithKline Research & Development Ltd


title:
A Phase Ib/IIa, Open-Label, Multicenter Clinical Trial to Assess Safety and Efficacy of the Human Anti-CD38 Antibody MOR202 in anti-PLA2R antibody positive Membranous Nephropathy (aMN) - M-PLACE

 Essai clinique de phase Ib/IIa multicentrique, en ouvert, visant à évaluer la sécurité d’emploi et l’efficacité de l’anticorps humain anti-CD38 MOR202 dans le cadre du traitement de la glomérulopathie  extramembraneuse avec anticorps anti-PLA2R (GEMa) – M-PLACE

lead_sponsor: MorphoSys AG


title: A Randomized, 6-Week, Double-Blind, Placebo-Controlled, Flexible-Dose, Parallel- Group Study of Lurasidone Adjunctive to Lithium or Divalproex for the Treatment of Bipolar I Depression

lead_sponsor: Dainippon Sumitomo Pharma America Inc.


title: A phase II multicentric study in adults with acute myelogenous leukaemia (AML) in first complete remission (CR1) using IV BuCy2 in a once daily Bu regimen targeting a narrow therapeutic window prior to hematopoietic stem cell transplantation.

lead_sponsor: PIERRE FABRE MEDICAMENT


title: An interventional, multicenter, single arm, phase I/IIa clinical trial to investigate the efficacy and safety of allo-APZ2-EB on epidermolysis bullosa (EB)

lead_sponsor: RHEACELL GmbH & Co. KG


title: A Long-term Follow-up Study of Subjects With β-thalassemia or Sickle Cell Disease Treated with Autologous CRISPR-Cas9 Modified Hematopoietic Stem Cells (CTX001)

lead_sponsor: Vertex Pharmaceuticals Incorporated


title: An Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of ISIS 420915 in Patients with Familial Amyloid Polyneuropathy (FAP)

lead_sponsor: Isis Pharmaceuticals, Inc


title:
Exploratory phase II study in patients after treatment of high grade brain tumors to assess the technical performance of Tc-99m tetrofosmin for differentiation of recurrence versus radiation necrosis

 Étude préliminaire phase II auprès de patients après traitement de tumeurs cérébrales de haut grade pour déterminer la performance technique du Tc-99m tétrofosmine pour différencier la tumeur récidivante de la nécrose de rayonnement

lead_sponsor: pro-ACTINA S.A.


title: MRX-800: A Long-Term Safety Study of Maralixibat, an Apical Sodium Dependent Bile Acid Transporter Inhibitor (ASBTi), in the Treatment of Cholestatic Liver Disease in Subjects Who Previously Participated in a Maralixibat Study.

lead_sponsor: Mirum Pharmaceuticals Inc.


title:
A randomized, treatment open-label, dose-blinded, parallel group, three arm, proof-of-concept clinical trial to investigate the efficacy and safety of LNP023 compared with rituximab in the treatment of subjects with idiopathic membranous nephropathy.

 Etude clinique de preuve de concept randomisée, à 3 groupes parallèles, avec traitement en ouvert et posologies en aveugle, visant à étudier l'efficacité et la sécurité d’emploi du LNP023 par rapport au rituximab dans le traitement des patients atteints de glomérulonéphrite extra-membraneuse idiopathique.

lead_sponsor: Novartis Pharma AG


title:
A Randomized, Phase 3, Double-blind, Placebo-controlled Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma

 Étude randomisée de phase 3, en double aveugle, contrôlée versus placebo, évaluant le traitement par pazopanib avec ou sans abexinostat chez des patients présentant un cancer du rein localement avancé ou métastatique

lead_sponsor: Xynomic Pharmaceuticals, Inc.


title:
Multicenter, open-label, safety and tolerability study of ascending doses of HepaStem in patients with cirrhotic and pre-cirrhotic non-alcoholic steatohepatitis (NASH).

 Étude multicentrique, en ouvert, évaluant la sécurité et la tolérance de doses croissantes d’HepaStem chez des patients atteints de stéatohépatite non-alcoolique (également appelé NASH) à un stade de cirrhose ou de pré-cirrhose.

lead_sponsor: Promethera Biosciences


title: A double-blind, placebo-controlled, randomized phase III trial to assess the safety and efficacy of Viaskin® Peanut in peanut-allergic young children 1-3 years of age (EPITOPE study)

acronym: EPITOPE

lead_sponsor: DBV TECHNOLOGIES S.A.


title: A 104 week, randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate the efficacy of aliskiren on the progression of atherosclerosis in patients  with coronary artery disease when added to optimal background therapy

lead_sponsor: Novartis Pharma Services AG


title: Randomised, double-blind, placebo-controlled dose-effect study of V0114 (2.5, 5, 7.5 and 10 mg) versus mequitazine 10 mg and placebo in the treatment of seasonal allergic rhinitis.


title: A 52-week, multi-center, randomized, double-blind, placebo-controlled, parallel group study in patients with mild Alzheimer’s Disease (AD) to investigate the safety and tolerability of repeated subcutaneous injections of CAD106.

acronym: Not applicable.


title: Evaluation of Belatacept as First-line Immunosuppression in De Novo Liver Transplant Recipients  Revised Protocol Number 01, incorporating Amendment 02 (version 1.0 dated 22-Oct-07)

lead_sponsor: Bristol-Myers Squibb International Corporation


title: Clinical study to evaluate the efficacy, safety and kinetics of Octagam® 10% for replacement therapy in Primary Immunodeficiency Diseases (PID)

lead_sponsor: Octapharma AG


title: FONDAparinux in patients with a plaster CAST (FONDACAST):  A Multicentre, Randomized, Open-label, Controlled, Two-Parallel-Group, Phase III Study to Evaluate the Efficacy and Safety of Fondaparinux versus Low-molecular-Weight Heparin (Nadroparin), in Patients Requiring Rigid or Semi-rigid Immobilization for at least 21 Days and up to 45 Days because of Isolated Non-surgical Below-Knee Injury

acronym: FONDACAST

lead_sponsor: GlaxoSmithKline R & D


title: Phase III, Multicenter, Open-label, Randomized Study of Erlotinib (Tarceva®) Treatment Versus Chemotherapy in Patients with Advanced Non-small-cell Carcinoma of the Lung Who Present Mutations in the Tyrosine Kinase (TK) Domain of Epidermal Growth Factor Receptor (EGFR)

lead_sponsor: Grupo Espagnol de Cancer de Pulmon


title: Phase II randomized trial of MEK inhibitor AS703026 or placebo combined with gemcitabine in chemo-naïve metastatic pancreas cancer subjects

lead_sponsor: Merck Serono S.A. - Geneva


title: A randomized phase II, open-label multicenter trial of panobinostat monotherapy in women with HER2 positive locally recurrent or metastatic breast cancer

lead_sponsor: Cancer International Research Group


title: A Randomized, Double blind, Placebo-Controlled Dose Escalation Study to Investigate the Safety and Pharmacokinetics after Single and Multiple Doses of SLV334 in Sequential Cohorts of Patients with Moderate and Severe Traumatic Brain Injury

lead_sponsor: Solvay Pharmaceuticals B.V.


title:
Thyroid hormone analog therapy of patients with severe psychomotor retardation caused by mutations in the MCT8 thyroid hormone transporter: The Triac Trial.

 Behandeling met een schildklierhormoon analoog bij patiënten met psychomotore retardatie veroorzaakt door een mutatie in de MCT8 schildklierhormoon transporter: de Triac Trial.

acronym:
Triac Trial in MCT8 patients

 Triac Trial in MCT8 patiënten.

lead_sponsor: Centre Hospitalier de Toulouse


title: A Multicenter, Open-Label Extension Study of WVE-210201 in Patients previously enrolled in WVE-DMDX51-001

lead_sponsor: Wave Life Sciences Ltd.


title: The Effect of Acadesine on Clinically Significant Adverse Cardiovascular and Cerebrovascular Events in High-Risk Subjects Undergoing Coronary Artery Bypass Graft (CABG) Surgery Using Cardiopulmonary Bypass (Protocol No. P05633): RED-CABG Trial (Reduction in Cardiovascular Events by Acadesine in Subjects Undergoing CABG)

acronym: RED-CABG Trial

lead_sponsor: Schering-Plough Research Institute, a Division of Schering Corporation


title: A randomised, double-blind, placebo-controlled, long-term Phase III study to assess the efficacy and safety of Oralgen® Grass Pollen in patients with grass pollen-related allergic rhinoconjunctivitis.

lead_sponsor: Artu Biologicals Europe B.V.


title: Phase I/II/III Pharmacokinetic and Outcome Study of Inspiration's Recombinant Factor IX Product, IB1001, in Subjects with Hemophilia B

lead_sponsor: Inspiration Biopharmaceuticals


title: CONNECTION PLUS:  An Open-Label Extension of the CONNECTION Protocol (DIM14) Evaluating Oral Dimebon in Patients with Alzheimer’s Disease

acronym: CONNECTION Plus

lead_sponsor: Medivation, Inc.


title: An open-label, randomised crossover pharmacokinetic, palatability and safety study to assess the bioavailability of a new 6MP oral liquid formulation by comparison to a currently registered 6MP 50 mg adult tablet (part A) followed by an open, non-randomised multiple-doses study with adjusted doses of 6MP oral liquid formulation (part B)  in children with acute lymphoblastic leukaemia.

lead_sponsor: Only For Children Pharmaceuticals


title: A 38-week extension to a 24 week multicenter, randomized, double-masked, placebo controlled study to assess the difference in the rate of recurrent exacerbations in Behçet’s patients with posterior or panuveitis treated with AIN457 vs placebo adjunctive to standard-of-care immunosuppressive therapy


title: Randomised phase II study evaluating, as first-line chemotherapy, weekly oral vinorelbine as a single-agent versus weekly paclitaxel as a single-agent in estrogen receptor positive, HER2 negative patients with advanced breast cancer.

lead_sponsor: PIERRE FABRE MEDICAMENT


title: OLMESARTAN +AMLOIPINE TREATMENT IN DIABETIC PATIENTS: EVALUATING BLOOD PRESSURE CONTROL AFTER 48 HOURS FROM THE LAST ADMINISTRATION (MISSED DOSE)

lead_sponsor: MENARINI INTERNATIONAL OPERATIONS LUXEMBOURG SA


title: A Phase 3, Multicenter, randomized, double-blind study evaluating the efficacy and safety of ABP 501 compared with Adalimumab in subjects with moderate to severe plaque psoriasis

lead_sponsor: Amgen Inc


title: A prospective randomised Phase III trial to evaluate optimal treatment duration of first-line bevacizumab in combination with carboplatin and paclitaxel in patients with primary epithelial ovarian, fallopian tube or peritoneal cancer.

acronym: The BOOST (Bevacizumab Ovarian Optimal Standard Treatment) Trial

lead_sponsor: AGO Research GmbH


title: SPIRonolactone In the Treatment of Heart Failure - A double-blind, randomized, placebo-controlled, parallel group, interventional phase III study to evaluate the efficacy and safety of spironolactone compared to placebo on the composite endpoint of recurrent heart failure hospitalizations and cardiovascular death in patients with heart failure with mid- range or preserved ejection fraction

lead_sponsor: Charité Universitätsmedizin Berlin


title: A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 1b/2a Study of WVE-120101 Administered Intrathecally in Patients with Huntington’s Disease

lead_sponsor: Wave Life Science Ltd.


title: An open label, prospective, multicenter trial, on the effect of anti-TNF alpha Chimeric monoclonal antibody (Infliximab, Remicade) on the inflammatory and fibrous lesions in patients with intestinal Crohn's Disease.

lead_sponsor: CHRU de Lille


title:
An international, multicentre, efficacy and safety study of I10E in
 initial and maintenance treatment of patients with Chronic
 Inflammatory Demyelinating Polyradiculoneuropathy

acronym: PRISM

lead_sponsor: LFB BIOTECHNOLOGIES


title:
A Prospective, Open-Label, Active-Controlled Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Efficacy of Rivaroxaban for Thromboprophylaxis in Pediatric Subjects 2 to 8 Years of Age after the Fontan Procedure

 Etude prospective, en ouvert, contrôlée versus traitement actif, pour évaluer la pharmacocinétique, la pharmacodynamie, la sécurité d’emploi et l’efficacité du rivaroxaban dans la thromboprophylaxie chez des patients âgés de 2 à 8 ans, ayant subi une procédure de Fontan

acronym: UNIVERSE

lead_sponsor: Janssen-Cilag International N.V


title:
A Phase 3 Open-Label, Single-Arm Study To Evaluate The Efficacy and Safety of BMN 270, an Adeno-Associated Virus Vector–Mediated Gene Transfer of Human Factor VIII at a dose of 4E13 vg/kg in Hemophilia A Patients with Residual FVIII Levels ≤ 1 IU/dL Receiving Prophylactic FVIII Infusions

 Étude de phase 3 ouverte, à un seul bras, destinée à évaluer l’efficacité et la sécurité du BMN-270, un vecteur viral adéno-associé pour le transfert de gène du facteur VIII humain à une dose de 4E13 vg/kg chez des patients atteints d’hémophilie A ayant des taux de base de FVIII ≤ 1 UI/dl et recevant des injections de FVIII en prophylaxie

lead_sponsor: BioMarin Pharmaceutical Inc.


title:
A Multicentre, Double-blind, Randomized, Placebo Controlled, Parallel
 Group, Phase 3, Safety Extension Study to Evaluate the Safety and Tolerability of Tezepelumab in Adults and Adolescents with Severe Uncontrolled Asthma
 (DESTINATION)

 Etude d’extension de phase III multicentrique, en double aveugle, randomisée, contrôlée contre placebo et en groupes parallèles, évaluant la sécurité d’emploi et la tolérance du Tezepelumab, chez des patients adultes et adolescents, présentant un asthme sévère non contrôlé (DESTINATION)

acronym: DESTINATION

lead_sponsor: AstraZeneca AB


title: An international phase III randomised trial comparing in severe Exacerbations of Chronic obstructive pulmonary  disease the efficacy of Helium/Oxygen versus Air/Oxygen administered during spontaneous breathing and intermittent non-invasive ventilation. The E.C.H.O. ICU trial

acronym: ECHO ICU trial

lead_sponsor: Air Liquide


title: An open label, 3-arm, Randomised phase II study to Compare the Safety and Efficacy of Ponatinib in combination with either Chemotherapy or Blinatumomab with Imatinib plus Chemotherapy as front-line therapy for patients aged 55 years and over with Philadelphia chromosome positive (Ph+ or BCR-ABL+) acute lymphoblastic leukemia (ALL)

lead_sponsor: Cardiff University


title: A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 1b/2a Study of WVE-120102 Administered Intrathecally in Patients with Huntington’s Disease

lead_sponsor: WAVE Life Sciences Ltd


title: A Phase 1/2a, Open Label, Dose Escalation, Safety Study of Intra-thrombus Plasmin (Human) Administration in Acute, Middle Cerebral Artery, Ischemic Stroke

lead_sponsor: Talecris Biotherapeutics Inc


title:
A Phase I Trial of NECTAR (Nelarabine, Etoposide and Cyclophosphamide in T-ALL Relapse): A Joint Study of TACL, POETIC and ITCC

 Essai de phase I NECTAR (Nélarabine, Etoposide et Cyclophosphamide dans les rechutes de LAL-T) : Une étude conjointe de TACL, POETIC et ITCC

acronym:
NECTAR trial

 Etude NECTAR

lead_sponsor: TACL


title: An open-label, multicenter study in male pediatric patients with cerebral X-linked Adrenoleukodystrophy (cALD) to assess the effect of MIN-102 treatment on disease progression prior to human stem cell transplant (HSCT)

lead_sponsor: Minoryx Therapeutics S.L.


title: A multicenter, international, randomised, double-blind, placebo controlled study to demonstrate the clinical efficacy and safety of a subcutaneous immunotherapy with gpASIT+™ in patients with grass pollen-induced allergic rhinoconjunctivitis

acronym: not availabe

lead_sponsor: BioTech Tools S.A.


title:
Treatment of High Grade Non-Muscle Invasive Urothelial Carcinoma of the Bladder by Standard Number and Dose of  Intravesical BCG Instillations Versus Reduced Number of Intravesical Instillations with Standard Dose of BCG.  A European Association of Urology Research Foundation Randomised Phase III Clinical Trial.

 Etude randomisée comparant le traitement standard de 15 instillations par BCG thérapie à un traitement allégé de 9 instillations chez les patients porteurs d’une tumeur de vessie n'infiltrant pas le muscle. Etude NIMBUS

acronym: NIMBUS

lead_sponsor: EAU Foundation for Urological Research


title: A Phase I/II, open label, multicenter study of the safety and efficacy of LAG525 single agent and in combination with PDR001 administered to patients with advanced malignancies

lead_sponsor: Novartis Pharma Services AG


title:
A Randomised, Open label, Multicentre, Phase 3 Trial of First line Treatment with Mesenchymal Stromal Cells MC0518 Versus Best Available Therapy in Adult and Adolescent Subjects with Steroid refractory Acute Graft versus host Disease After Allogeneic Haematopoietic Stem Cell Transplantation (IDUNN Trial)

 Étude de phase III randomisée, multicentrique, en ouvert portant sur le traitement de première intention par cellules stromales mésenchymateuses MC0518 par rapport au meilleur traitement disponible chez des patients adultes ou adolescents présentant la forme aiguë de la maladie du greffon contre l'hôte réfractaire aux stéroïdes, suite à une greffe de cellules souches hématopoïétiques allogéniques (étude IDUNN)

acronym: IDUNN

lead_sponsor: medac Gesellschaft für klinische Spezialpräparate mbH


title:
An Open-Label, Multinational, Phase 1/2 Study of the Safety and Dose Escalation of SHP648, an Adeno-Associated Virus Serotype 8 (AAV8) Vector Expressing FIX Padua in Hemophilia B Subjects

 Étude de phase I/II internationale en ouvert évaluant la sécurité d’emploi et l’escalade de dose du SHP648, un vecteur viral adéno-associé de sérotype 8 (AAV8) exprimant le facteur IX Padua chez des patients atteints d’hémophilie B

lead_sponsor: Baxalta Innovations GmbH


title: A phase 2/3 prospective, multicentre randomized, double-blind trial, comparing intra-discal allogeneic adult BM-MSC therapy and sham-treated controls in subjects with chronic low back pain due to lumbar degenerative disc disease (DDD) unresponsive to conventional therapy

lead_sponsor: University Hospital of Montpellier


title:
A Phase 2 Study of Poziotinib in Patients with Non-Small Cell Lung Cancer, Locally Advanced or Metastatic, with EGFR or HER2 Exon 20 Insertion Mutation (POZITIVE20-1)

 Étude de phase II sur le poziotinib chez des patients atteints d'un cancer du poumon non à petites cellules, localement avancé ou métastatique, ayant une mutation par insertion au niveau de l’exon 20 de l’EGFR ou de l’HER2 (POZITIVE20-1)

lead_sponsor: Spectrum Pharmaceuticals, Inc.


title: A Phase III, open-label, randomized, controlled multi-center study of the efficacy of L19IL2/L19TNF neoadjuvant intratumoral treatment followed by surgery versus surgery alone in clinical stage IIIB and IIIC melanoma patients.

acronym: Neoadjuvant L19IL2/L19TNF- Pivotal study

lead_sponsor: Philogen S.p.A.


title: Treatment of steroid refractory gastro-intestinal acute graft-versus-Host disEase afteR AllogeneiC hematopoietic stem celL transplantation with fEcal microbiota transfer (HERACLES)

acronym: HERACLES

lead_sponsor: MaaT Pharma


title: A randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of safinamide 100 mg once daily, as add-on therapy, in idiopathic Parkinson’s Disease (IPD) patients with motor fluctuations and PD related chronic pain

acronym: Pain study

lead_sponsor: Zambon SpA


title:
A Phase II, Single Arm, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of MOR00208 Combined with Idelalisib in Patients with Relapsed or Refractory CLL/SLL Previously Treated with Bruton’s Tyrosine Kinase (BTK) Inhibitor.

 Étude de phase II, multicentrique, en ouvert, sur groupe unique visant à évaluer l’efficacité et la sécurité d’emploi du MOR00208 en association avec l’idelalisib chez les patients atteints de LLC/PLL récidivant ou réfractaire précédemment traité par l’inhibiteur de la tyrosine kinase de Bruton (BTK)

lead_sponsor: MorphoSys AG


title: COLCHICINE CORONAVIRUS SARS-CoV2 TRIAL

acronym: COLCORONA

lead_sponsor: Montreal Heart Institute Coordinating Centre


title: PHASE III, MULTI-CENTER, RANDOMIZED, 48 WEEKS, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED STUDY TO EVALUATE EFFICACY AND SAFETY OF CER-001 ON VESSEL WALL AREA IN PATIENTS WITH GENETICALLY DEFINED FAMILIAL PRIMARY HYPOALPHALIPOPROTEINEMIA AND RECEIVING BACKGROUND OPTIMIZED LIPID THERAPY

acronym: TANGO

lead_sponsor: CERENIS THERAPEUTICS SA


title: An Open-label, Single-dose, Safety and Pharmacokinetic Study of Regadenoson in Paediatric Patients

lead_sponsor: GE Healthcare Ltd.


title: An International, Multi-Center, Double-Blind, Randomized, Phase III Trial of 90Y-Clivatuzumab Tetraxetan plus Low-Dose Gemcitabine Versus Placebo plus Low-Dose Gemcitabine in Patients with Metastatic (Stage IV) Pancreatic Adenocarcinoma Who Received at Least Two Prior Treatments (PANCRIT-1)

acronym: PANCRIT-1 (PANcreatic Cancer RadioImmunoTherapy Trial 1)

lead_sponsor: Immunomedics, Inc.


title: A Phase 1/2, open-label, multicenter, dose escalation and dose expansion study of NKTR-214 and Nivolumab in patients with select locally advanced or metastatic solid tumor malignancies

lead_sponsor: Nektar Therapeutics


title: A Phase III, Multicenter, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination with Pomalidomide and Dexamethasone (B-Pd) versus Pomalidomide plus Bortezomib and Dexamethasone (PVd) in Participants with Relapsed/Refractory Multiple Myeloma (DREAMM 8)

lead_sponsor: GlaxoSmithKline Research & Development Limited


title: A Phase 2 Study of Panitumumab Plus Irinotecan Followed by Panitumumab Plus AMG 479 in Subjects With Metastatic Colorectal Carcinoma Expressing Wild Type KRAS and Refractory to Oxaliplatin- or Irinotecan- and Oxaliplatin-containing Regimens to Evaluate Mechanisms of Acquired Resistance to Panitumumab

lead_sponsor: Amgen Inc


title: Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered NY-ESO-1-Specific (c259) T Cells, alone or in combination with other agents, in HLA-A2+ Participants with NY-ESO-1 and/or LAGE-1a Positive Solid Tumors (IGNYTE-ESO)

acronym: Assessment of safety & antitumor activity of GSK3377794 in NY-ESO-1+ and/or LAGE-1a+ solid tumors

lead_sponsor: GlaxoSmithKline Research & Development Ltd


title: A Phase 2 Open-Label Study to Evaluate the Safety and Efficacy of DCR-PHXC in Patients With Primary Hyperoxaluria Type 1 or 2 and Severe Renal Impairment, With or Without Dialysis

acronym: PHYOX 7: Safety & Efficacy of DCR-PHXC in patients with PH1/2 and ESRD

lead_sponsor: Dicerna Pharmaceuticals Inc

status: Not Authorised


title: BT8009-100:  Phase I/II Study of the Safety, Pharmacokinetics, and Preliminary Clinical Activity of BT8009 in Patients with Nectin-4 Expressing Advanced Malignancies

lead_sponsor: BicycleTx Ltd.


title: Reduced dose-density of denosumab for maintenance therapy of unresectable giant cell tumor of bone: a multicenter phase II study "REDUCE"

lead_sponsor: European Organisation for Research and Treatment of Cancer (EORTC)


title: An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined with a Tyrosine Kinase Inhibitor (TKI) in Patients with Relapsed or Refractory Ph+ Chronic Myeloid Leukemia (CML)

lead_sponsor: Kartos Therapeutics, Inc.


title: An open-label, multicenter, multinational extension study of the long-term safety and pharmacokinetics of repeated biweekly infusions of neoGAA in patients with Pompe disease

lead_sponsor: Genzyme Corporation


title:
An open-label, non-randomized study on efficacy, pharmacokinetics, pharmacodynamics, safety and tolerability of LNP023 in two patient populations with C3 glomerulopathy

 Etude non randomisée, en ouvert, portant sur l'efficacité, la pharmacocinétique, la pharmacodynamie, la sécurité d’emploi et la tolérance du LNP023 chez deux populations de patients atteints de glomérulopathie C3

lead_sponsor: Novartis Pharma AG


title: A Phase 2 multicenter, randomized, placebo controlled, double-blind study to assess the safety and efficacy of CC-486 (oral azacitidine) in combination with pembrolizumab (MK-3475) versus pembrolizumab plus placebo in subjects with previously treated locally advanced or metastatic non-small cell lung cancer

lead_sponsor: Celgene Corporation


title:
An Open-Label, Multi-Centre, Randomised Study to Investigate Integrase Inhibitor Versus Boosted Protease Inhibitor Antiretroviral Therapy for Patients with Advanced HIV Disease. The Late Presenter Treatment Optimisation Study (LAPTOP).

 Étude en ouvert, multicentrique, randomisée, visant à étudier le traitement antirétroviral par inhibiteur de l’intégrase, par rapport au traitement antirétroviral par inhibiteur de la protéase boosté, chez des patients atteints du VIH de stade avancé. Etude d’optimisation du traitement des patients dépistés tardivement (LAPTOP : The Late Presenter Treatment Optimisation Study)

acronym:
LAPTOP - Late Presenter Treatment Optimisation Study

 LAPTOP - Etude d’optimisation du traitement des patients dépistés tardivement

lead_sponsor: NEAT ID Foundation


title:
A Phase III Randomized, Double-Blind Placebo Controlled, Multi-Regional, International Study of Durvalumab in Combination with Gemcitabine plus Cisplatin Versus Placebo in Combination with Gemcitabine plus Cisplatin for Patients With First-Line Advanced Biliary Tract Cancers (TOPAZ-1)

 Étude internationale, multirégionale, de phase III randomisée, en double aveugle, contrôlée versus placebo, comparant en traitement de 1ère ligne le durvalumab en association avec la gemcitabine et le cisplatine à un placebo en association avec la gemcitabine et le cisplatine chez des patients atteints d’un cancer des voies biliaires avancé (étude TOPAZ-1)

acronym: TOPAZ-1 Study

lead_sponsor: AstraZeneca AB


title:
A Phase 2, randomised, multicentre study to assess the dose level of multiple THR-149 injections and to evaluate the efficacy and safety of THR-149 versus aflibercept for the treatment of diabetic macular oedema (DME)

 Étude de phase 2 multicentrique, randomisée, visant à évaluer le niveau de dose de plusieurs injections de THR-149, ainsi que l’efficacité et la sécurité du THR-149 comparé à l’aflibercept dans le traitement de l’oedème maculaire diabétique (OMD)

acronym: KALAHARI

lead_sponsor: Oxurion NV


title:
An Open-label, Phase 1b/2 Study of ACP-196 in Subjects
 with Waldenström Macroglobulinemia

 Etude ouverte de phase 1b/2 de l'ACP-196 chez des patients atteints d'une Macroglobulinémie de Waldenström

lead_sponsor: Acerta Pharma BV


title: A multicenter study with an open-label Phase Ib part followed by a randomized, placebo-controlled, double-blind, Phase II part to evaluate efficacy, safety, tolerability, and pharmacokinetics of the DNA-PK inhibitor M3814 in combination with capecitabine and radiotherapy in participants with locally advanced rectal cancer

lead_sponsor: Merck KGaA


title:
A Phase II Randomised, Multi-Centre Study to Investigate the Efficacy and Tolerability of a Second Maintenance Treatment in Patients with Platinum-Sensitive Relapsed Epithelial Ovarian Cancer, who have Previously Received PARP Inhibitor Maintenance Treatment

 Étude de phase II, multicentrique, randomisée, destinée à évaluer l’efficacité et la tolérance d’un deuxième traitement d’entretien chez des patientes présentant un cancer épithélial de l’ovaire en rechute platine-sensible, ayant reçu préalablement un premier traitement d’entretien par inhibiteur de PARP


title: A Phase II, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects with INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma

lead_sponsor: Epizyme, Inc.


title: A Phase 2, Open-Label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations

lead_sponsor: Incyte Corporation


title:
Phase III randomized clinical trial for stage III epithelial ovarian cancer randomizing between primary cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy

 Etude de phase 3 randomisée multicentrique et internationale comparant la chirurgie de cytoréduction première avec ou sans chimiohyperthermie intrapéritonéale dans les cancers épithéliaux de l’ovaire de stade III

acronym:
OVHIPEC-2

 OVHIPEC-2

lead_sponsor: Institut du Cancer de Montpellier


title: Phase 1-2 Study of the Safety, Pharmacokinetics, and Preliminary Activity of ASTX660 in Subjects with Advanced Solid Tumors and Lymphomas

lead_sponsor: Astex Pharmaceuticals, Inc.


title:
Phase 1 / 2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects with Non-Small Cell Lung Cancer with c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors

 Étude de phase I/II multicentrique visant à évaluer la sécurité d'emploi, la pharmacocinétique et l'efficacité préliminaire d'APL-101 chez des patients atteints de cancer bronchique non à petites cellules avec mutations par saut de l'exon 14 de c-MET et des patients atteints de tumeurs solides avancées avec dérégulation de c-MET

acronym: SPARTA

lead_sponsor: Apollomics, Inc.


title: A Phase 3, Multicenter, Randomized, Double-Blind Study of the Efficacy and Safety of Rezafungin for Injection Versus the Standard Antimicrobial Regimen to Prevent Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation (The ReSPECT Study)

acronym: ReSPECT

lead_sponsor: Cidara Therapeutics Inc.


title:
Adjustable brodalumab dosage regimen compared with standard brodalumab treatment for 52 weeks in subjects with moderate-to-severe plaque psoriasis and ≥120 kg body weight

 Traitement par brodalumab selon un schéma posologique adaptable par rapport à un traitement standard par brodalumab pendant 52 semaines chez des patients atteints de psoriasis en plaques modéré à sévère et pesant au moins 120 kg

acronym: ADJUST

lead_sponsor: LEO Pharma A/S


title: A pilot, open-label, single arm, multicenter study to evaluate safety, tolerability, pharmacokinetics and efficacy of intravenous administrations of NI-0501, an anti-interferon gamma (anti-IFNγ) monoclonal antibody, in patients with systemic Juvenile Idiopathic Arthritis (sJIA) developing Macrophage Activation Syndrome/secondary HLH  (MAS/sHLH)

lead_sponsor: Novimmune SA


title:
A Phase 3 Single Arm Study Evaluating the Efficacy and Safety of Gene Therapy in Subjects with Transfusion-dependent β-Thalassemia, who have a β0/β0 Genotype, by Transplantation of Autologous CD34+ Stem Cells Transduced Ex Vivo with a Lentiviral βA-T87Q Globin Vector in Subjects ≤50 Years of Age

 Étude de phase 3 à bras unique évaluant l’efficacité et la sécurité de la thérapie génique par greffe de cellules souches autologues CD34+ transduites ex vivo avec un vecteur lentiviral βA-T87Q-globine chez des patients, âgés de 50 ans ou plus, atteints d’une bêta-thalassémie dépendante des transfusions et ayant le génotype β0/β0

lead_sponsor: bluebird bio, Inc.


title:
A Phase 3 Single Arm Study Evaluating the Efficacy and Safety of  Gene Therapy in Subjects with Transfusion-dependent β- Thalassemia, who do not have β0/β0 Genotype, by Transplantation of Autologous CD34+ Stem Cells Transduced Ex Vivo with a Lentiviral βA-T87Q-Globin Vector in Subjects ≤50 Years of Age

 Étude de phase 3 à bras unique évaluant l’efficacité et la sécurité de la thérapie génique par greffe de cellules souches autologues CD34+ transduites ex vivo avec un vecteur lentiviral βA-T87Q-globine chez des patients, âgés de 50 ans ou plus, atteints d’une bêta-thalassémie dépendante des transfusions et n’ayant pas de génotype β0/β0


title: A Combined Phase 2/3 12-week, Randomized, Double-blind, Placebo-controlled Study Investigating the Efficacy of AMT-101 in Subjects with Chronic Antibiotic-resistant Pouchitis

lead_sponsor: Applied Molecular Transport Inc.


title:
A Phase II, Open-Label, Multi-Centre, International Safety Study of Durvalumab Following Sequential Chemotherapy and Radiation Therapy in Patients with Stage III, Unresectable Non-Small Cell Lung Cancer (PACIFIC 6)

 Étude de phase II internationale, multicentrique, menée en ouvert, évaluant la sécurité d’utilisation du durvalumab après une chimiothérapie et une radiothérapie séquentielles chez des patients présentant un cancer bronchique non à petites cellules non résécable de stade III (PACIFIC 6)

acronym: PACIFIC 6


title:
PEACE (Pegzilarginase Effect on Arginase 1 Deficiency Clinical Endpoints): A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of the Efficacy and Safety of Pegzilarginase in Children and Adults with Arginase 1 Deficiency

 Étude PEACE (Pegzilarginase Effect on Arginase 1 Deficiency Clinical Endpoints [effets de la pegzilarginase sur les critères d’évaluation cliniques relatifs au déficit en arginase 1]) : Une étude de phase III, randomisée, en double aveugle, contrôlée contre placebo, visant à évaluer l’efficacité et la sécurité d’emploi de la pegzilarginase chez des enfants et des adultes présentant un déficit en arginase 1.

lead_sponsor: Aeglea Biotherapeutics, Inc.


title:
A Prospective, Open-label, Long-term Safety and Efficacy Study of
 Teduglutide in Pediatric Patients with Short Bowel Syndrome Who
 Completed TED-C14-006 or SHP633-301

 Original PIP P/238/2010

lead_sponsor: Shire Human Genetic Therapies, Inc.


title:
Multi-Centre, Randomized, Double-Blind, Placebo-Controlled, Efficacy, and Safety Study of Etripamil Nasal Spray for the Termination of Spontaneous Episodes of Paroxysmal Supraventricular Tachycardia
 The RAPID Study (NODE-301 Part 2)

lead_sponsor: Milestone Pharmaceuticals Inc.


title: Phase II Study of ZK 219477 in patients with recurrent glioblastoma

lead_sponsor: European Organisation for Research and Treatment of Cancer


title: A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, LONG-TERM EXTENSION STUDY TO DETERMINE THE SAFETY, TOLERABILITY, AND PRELIMINARY LONG TERM EFFICACY OF LECOZOTAN (SRA-333) SR IN PATIENTS WITH MILD TO MODERATE ALZHEIMER’S DISEASE

lead_sponsor: Wyeth Research Division of Wyeth Pharmaceuticals Inc., Clinical Research and Development


title: A PHASE IIIB, RANDOMIZED, ACTIVE CONTROLLED OPEN-LABEL STUDY OF SUNITINIB (SUTENT) 37.5 MG DAILY VS IMATINIB MESYLATE 800 MG DAILY IN THE TREATMENT OF PATIENTS WITH GASTROINTESTINAL STROMAL TUMORS (GIST) WHO HAVE HAD PROGRESSIVE DISEASE WHILE ON 400 MG DAILY OF IMATINIB

lead_sponsor: Pfizer Inc., 235 East 42nd Street, New York, NY 10017


title: A Phase IIb, Multi-Center, Double-Blind, Randomized, Placebo-Controlled Study, Evaluating the Safety, Tolerability and Efficacy of RO4607381 by Measuring Flow Mediated Dilatation in the Brachial Artery, 24 hour Ambulatory Blood Pressure, Lipids, Lipoproteins and Markers Vascular Inflammation, Oxidation and CV risk in Patients with Coronary Heart Disease (CHD) or CHD Risk Equivalents

lead_sponsor: F.Hoffmann-La Roche Ltd.


title: A randomised, double-blind, placebo controlled, multi-centre, exploratory, pilot, phase II trial of 150 mg atacicept given subcutaneously in combination with rituximab in subjects with rheumatoid arthritis.

acronym: Atacicept in combination with rituximab in subjects with rheumatoid arthritis

lead_sponsor: Merck Serono International


title: Randomized, Double-Blind, Placebo-Controlled Study of Efficacy and Safety of Donepezil Hydrochloride in Preadolescent and Adolescent Children with Attention Impairment Following Cancer Treatment

lead_sponsor: Eisai Limited


title: A Randomized, Double-Blind, Placebo-Controlled, Parallel Design, Multinational Study to Evaluate the Efficacy and Safety of Tadalafil 2.5 and 5 mg Once Daily Dosing for 12 Weeks for the Treatment of Erectile Dysfunction and Signs and Symptoms of Benign Prostatic Hyperplasia in Men with Both Erectile Dysfunction and Benign Prostatic Hyperplasia.

acronym: LVHR

lead_sponsor: Eli Lilly and Company


title: Efficacy and Safety comparison of Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel associated with Lymecycline 300mg Capsules versus Adapalene 0.1% / Benzoyl Peroxide 2.5% Vehicle Gel associated with Lymecycline 300mg Capsules in the Treatment of  Moderate to Severe Acne Vulgaris.

acronym: TEAM - Tetralysal Epiduo = Acne Makeover

lead_sponsor: Galderma Research & Development


title: A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared with Best Supportive Care in Patients with COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome

lead_sponsor: Alexion Pharmaceuticals, Inc.


title: A randomized, multicenter, double-blind, placebo-controlled, Phase 2/3 study of the Bruton’s Tyrosine Kinase inhibitor ibrutinib in combination with nab-paclitaxel and gemcitabine versus placebo in combination with nab-paclitaxel and gemcitabine, in the first line treatment of patients with metastatic pancreatic adenocarcinoma

lead_sponsor: Pharmacyclics LLC


title: A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy after Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer

acronym:
PATINA

 PATINA

lead_sponsor: Alliance Foundation Trials, LLC


title: A randomised, open label, parallel-group, multi-centre trial to compare the efficacy and safety of TachoSil versus standard haemostatic treatment in the cardiovascular surgery

acronym: TachoSil versus standard haemostatis treatment of haemorrhage in cardiovascular surgery

lead_sponsor: Nycomed Danmark ApS


title: A PHASE II, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE SAFETY AND EFFICACY OF SINGLE-AGENT LENALIDOMIDE (REVLIMID®) IN SUBJECTS WITH RELAPSED OR REFRACTORY AGGRESSIVE NON-HODGKIN’S LYMPHOMA

lead_sponsor: Celgene Corporation


title: Multicenter parallel phase II trial of BI 2536 administered as one hour i.v. infusion every 3 weeks in defined cohorts of patients with various solid tumours. A new drug screening program of the EORTC Network of Core Institutions (NOCI)

acronym: Phase II trial of BI 2536 in pts with various solid tumors

lead_sponsor: Boehringer Ingelheim France SAS


title: Study to Evaluate the Dose, Safety and Effectiveness of Modified-Release Recombinant Human Thyroid Stimulating Hormone (MRrhTSH) When Used in Conjunction with Radioiodine for the Treatment of Multinodular Goiter

lead_sponsor: Genzyme Europe BV


title: An 18-week, International, Multi-centre, Randomized, Parallel-group, Double-Blind, Active-Controlled Phase IIIb Study to Evaluate the Efficacy and Safety of Saxagliptin in combination with Metformin in Comparison with Sitagliptin in combination with Metformin in Adult Patients with Type 2 Diabetes Who Have Inadequate Glycaemic Control on Metformin Therapy alone

lead_sponsor: AstraZeneca AB


title: CONNECTION: A Global Phase 3, Double-Blind, Placebo-Controlled Safety and Efficacy Study of Oral Dimebon in Patients with Mild-to-Moderate Alzheimer’s Disease

acronym: CONNECTION

lead_sponsor: Medivation, Inc.


title: An open-label, multicenter protocol providing pegylated interferon alfa-2a (PEGASYS) as monotherapy or in combination with ribavirin (COPEGUS) for patients with chronic hepatitis C who have participated in previous Roche or Roche partner protocols.

lead_sponsor: F. Hoffmann-La Roche Ltd


title: A Randomized, Double-Blind, Placebo- and Active-Controlled Study of Carisbamate in the Treatment of Neuropathic Pain in Diabetic Peripheral Neuropathy Followed by a Blinded Extension Phase

lead_sponsor: Janssen Cilag International NV


title: Evaluation of the effect of 6 months treatment with V0191 on symptoms changes in patients with Mild Cognitive Impairment. Multicentre, randomised, double-blind, placebo-controlled study in parallel groups.

lead_sponsor: PIERRE FABRE MEDICAMENT - IDPF


title: A Randomised, Double-Blind, Placebo-Controlled, Multi-Centre Study to Evaluate the Safety and Efficacy of Eltrombopag to Reduce the Need for Platelet Transfusion in Thrombocytopenic Subjects with Chronic Liver Disease Undergoing Elective Invasive Procedures.

acronym: ELEVATE

lead_sponsor: GlaxoSmithKline Research and Development Ltd


title: A Randomized, Open-Label, Multicenter Phase 2 Study of VELCADE With Fludarabine in Comparison to Rituximab With Fludarabine in Follicular Lymphoma Subjects Previously Treated With Rituximab

lead_sponsor: Janssen-Cilag International NV


title: A Randomized, Double-Blind, Placebo Controlled, Multiple Dose Phase 2 Study to Determine the Safety and Efficacy of AMG 853 in Subjects with Inadequately Controlled Asthma

lead_sponsor: Amgen Inc


title:
A Phase 1/2 Study of ALKS 4230 Administered Subcutaneously
 as Monotherapy and in Combination With Pembrolizumab in
 Subjects With Advanced Solid Tumors
 (ARTISTRY-2)

 Étude de phase 1/2 sur l’ALKS 4230 administré par voie sous-cutanée en monothérapie et en association avec le pembrolizumab à des sujets présentant des tumeurs solides à un état avancé - ARTISTRY-2 (001)

lead_sponsor: Alkermes, Inc.


title: A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP STUDY, COMPARING THE EFFICACY AND TOLERABILITY OF ZIPRASIDONE (ZELDOX®, GEODON®) VS OLANZAPINE (ZYPREXA®) IN THE TREATMENT AND MAINTENANCE OF RESPONSE IN PATIENTS WITH ACUTE MANIA

acronym: ZOOM STUDY: ZIPRASIDONE AND OLANZAPINE’S OUTCOMES IN MANIA

lead_sponsor: Pfizer Ltd - Sandwich Laboratories


title: A Randomized, Double-Blind, Placebo-Controlled, Polysomnography plus Outpatient Study to Determine the Safety and Efficacy of 4 mg Ramelteon in Adults with Chronic Insomnia

lead_sponsor: Takeda Global Research & Development Centre (Europe) Ltd.


title: Efficacy and safety of 2 doses of S 90098 (1 and 2mg/day), sublingual formulation for 8 weeks in out-patients with Major Depressive Disorder. An 8-week randomised, double-blind, fixed dose, international, multicentre, placebo-controlled study with parallel groups, followed by an extension double-blind treatment period for 16 weeks.

lead_sponsor: Institut de Recherches Internationales Servier


title: An open label, single-arm, baseline-controlled, multicenter study to evaluate the efficacy, safety and immunogenicity of subcutaneous HX575 administered once a week (qw) and once every two weeks (q2w) in the treatment of anemia associated with chronic kidney disease in pre-dialysis and dialysis subjects

acronym: SWEEP Study

lead_sponsor: Hexal AG


title: A Phase 2 Study of Multiple Intravenous Doses of LY2127399, an Anti-BAFF Human Antibody, in Patients with Rheumatoid Arthritis on Concomitant Methotrexate and an Inadequate Response to TNFα Inhibitor Therapy

acronym: BCDG

lead_sponsor: Eli Lilly and Company


title: Randomised double blind placebo controlled pivotal study to evaluate efficacy and safety of rPhleum in adult and adolescent patients suffering from rhinoconjunctivitis +/- controlled Asthma

acronym: 2nd pivotal rPhleum

lead_sponsor: Allergopharma Joachim Ganzer KG


title: A multicenter, multinational phase II study to assess the clinical safety and feasibility of T-DM1 sequentially with anthracyline-based chemotherapy, as adjuvant or neoadjuvant therapy for patients with early stage HER2-positive breast cancer.


title: A randomized, double-blind, placebo-controlled, parallel group, fixed-dose, 8-week treatment, multi-center trial evaluating the dose effect relationship for efficacy and the safety of 3 oral doses of surinabant: 2.5, 5 and 10mg/day as an aid to smoking cessation in cigarette smokers

acronym: SURSMOKE

lead_sponsor: sanofi-aventis recherche et développement


title: A Randomized, Double-Blind, Parallel-Group, International Study to Evaluate the safety and Efficacy of Ocrelizumab Given as a Single Infusion or Dual Infusion Compared with Placebo in Patients with Active Rheumatoid Arthritis Who Have an inadequate Response to Methotrexate Therapy


title: 13-week, double-blind, placebo-controlled, fixed-dose, multicenter study to evaluate the efficacy and safety of AFQ056 in reducing moderate to severe L-dopa induced dyskinesias in patients with Parkinson’s disease

lead_sponsor: Novartis Pharma AG


title: A Phase III Randomised Double-blind Study Comparing Sorafenib With Placebo In Patients With Resected Primary Renal Cell Carcinoma at High or Intermediate Risk of Relapse

acronym: SORCE

lead_sponsor: Medical  Research Council


title: AN OPEN-LABEL, RANDOMIZED, CONTROLLED, PHASE 2 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF PEGCETACOPLAN IN THE TREATMENT OF POST-TRANSPLANT RECURRENCE OF C3G OR IC‑MPGN

acronym: NOBLE

lead_sponsor: Apellis Pharmaceuticals, Inc.


title: PREvention of STroke in Intracerebral haemorrhaGE survivors with Atrial Fibrillation (PRESTIGE-AF)

acronym: PRESTIGE-AF

lead_sponsor: Imperial College of Science, Technology and Medicine


title: LENS – Long-term Eltrombopag ObservatioNal Study - A long term observational ocular safety study in adults who have received study medication (SB-497115-GR / eltrombopag olamine or placebo) in a phase II or III clinical study evaluating eltrombopag

acronym: LENS


title: A 12-Week, International, Multicenter, Double-Blind, Randomized, Placebo-Controlled Comparison of the Efficacy and Safety of Oral UT-15C Sustained Release Tablets in Subjects with Pulmonary Arterial Hypertension

acronym: FREEDOM-M

lead_sponsor: United Therapeutics Corporation


title: Effect of inhalation of a free combination of tiotropium once daily 18 mcg and salmeterol twice daily 50 mcg versus a fixed combination of fluticasone and salmeterol twice daily (500/50 mcg) on static lung volumes and exercise tolerance in COPD patients (a randomized, double-blind, double dummy, 16 (2 x 8) weeks, crossover study)

acronym: Octane

lead_sponsor: Boehringer Ingelheim


title: Phase II Trial of Pemetrexed in Second Line Advanced/Metastatic Osteosarcomas

lead_sponsor: Eli Lilly and Company Limited


title: A Phase 2 Rollover Protocol of Telaprevir (VX-950) in Combination with Peginterferon Alfa-2a (Pegasys®) and Ribavirin (Copegus®) in Subjects Enrolled in the Control Group (Group A) of Study VX06-950-106, VX05-950-104 and VX05-950-104EU Who did not Achieve or Maintain an Undetectable HCV RNA Level Through Sustained Viral Response

acronym: Rollover Study of Telaprevir (VX-950), Pegasys, and Copegus in Hepatitis C

lead_sponsor: Vertex Pharmaceuticals Incorporated


title: A placebo controlled randomized, 12-week, dose-ranging, double-blind study versus placebo using tolterodine as a study calibrator, to evaluate efficacy and safety of SSR240600C in women with overactive bladder including urge urinary incontinence

lead_sponsor: sanofi-aventis recherche & développement


title: A phase 1/2, open-label study of bosutinib administered in combination with capecitabine in subjects with solid tumor and ErbB2 negative locally advanced or metastatic breast cancer.

lead_sponsor: Wyeth Research Division of Wyeth Pharmaceuticals Inc


title: Efficacy and safety of 3 doses (0.25, 0.5 and 1mg/day) of agomelatine sublingual administration over an 8-week treatment period, in out-patients with Major Depressive Disorder.  An 8-week randomised, double-blind, fixed dose, international multicentre, placebo-controlled study with parallel groups, followed by an extension double-blind treatment period of 16 weeks.


title: A multinational, multicenter, single blood sampling exploratory pharmacogenetic study of the REGARD (the REbif vs Glatiramer Acetate in Relapsing MS Disease) trial

acronym: REGARD-PGx

lead_sponsor: Merck Serono S.A. - Geneva


title: A 24 month extension to a 12-month open label, randomized, multicenter study evaluating efficacy, safety and tolerability of oral AEB071 plus tacrolimus (converted to myfortic® after 3 months), vs. myfortic® plus tacrolimus in de novo renal transplant recipients

lead_sponsor: Novartis Pharma Services AG


title: A Phase II, Randomized, Double-Blinded, Multicenter, Dose Finding Study Evaluating the Efficacy and Safety of the HCV Polymerase Inhibitor Prodrug (RO4588161) when given in combination with Pegasys® and Copegus® versus the currently approved combination of Pegasys® and Copegus® in Treatment-Naive Patients with Chronic Hepatitis C Genotype 1 Virus infection

lead_sponsor: F.  Hoffmann-La Roche Ltd


title: A blinded, randomized, placebo-controlled trial in genotype 1 hepatitis C-infected subjects to evaluate the efficacy, safety, tolerability and pharmacokinetics of repeated doses of TMC435350, with or without peginterferon alpha-2a and ribavirin.

lead_sponsor: Tibotec Pharmaceuticals Ltd


title: A Phase 2, Randomized, Open-label Study of Bosutinib Administered in Combination With Exemestane vs. Exemestane Alone as Second Line Therapy in Post-Menopausal Women with Locally Advanced or Metastatic ER+/PgR+/Her2- Breast Cancer

lead_sponsor: Wyeth Research Division of Wyeth Pharmaceuticals Inc.


title:
A prospective, multicenter, open-label, centrally allocated, active-controlled, phase 2 study to evaluate the efficacy and safety of masitinib in combination with gemcitabine versus gemcitabine alone in advanced/metastatic epithelial ovarian cancer patients in second line being refractory to first line platinum treatment or in third line.

 Etude de phase 2, prospective, multicentrique, en ouvert, avec allocation centralisée, contrôlée, visant à comparer l'efficacité et la tolérance de masitinib en association avec gemcitabine versus gemcitabine seule, chez des patientes atteintes d'un cancer de l’ovaire épithélial métastatique/avancé en 2ème ligne de traitement réfractaire à une première ligne de traitement avec sels de platine ou en 3ème ligne de traitement

lead_sponsor: AB Science


title: A Phase III double blind, randomised, placebo-controlled study of the efficacy, safety and tolerability of idebenone in the treatment of Friedreich's Ataxia patients.

lead_sponsor: Santhera Pharmaceuticals (Switzerland) Limited


title: Effects of agomelatine (25 to 50 mg/day) on sleep EEG parameters compared to escitalopram in patients with Major Depressive Disorder. A 6-week randomised, double-blind parallel groups study versus comparator, followed by a double-blind optional treatment extension period up to 6 months.

lead_sponsor: Institut de Recherches Internationales Servier


title: A Randomised, Open-Label Preliminary Study To Assess The Effects Of Etanercept 50 mg Once Weekly For 24 Weeks And Etanercept 50 mg Twice Weekly For 12 weeks Reducing To Etanercept 50 mg Once Weekly For 12 weeks On Nail And Skin Symptoms In Patients With Nail Psoriasis And Plaque Psoriasis.

lead_sponsor: Wyeth Pharmaceuticals France


title: A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, LONG-TERM EXTENSION STUDY TO DETERMINE THE SAFETY, TOLERABILITY, AND PRELIMINARY LONG TERM EFFICACY OF LECOZOTAN (SRA-333) SR IN PATIENTS WITH MILD TO MODERATE ALZHEIMER’S DISEASE TREATED WITH A CHOLINESTERASE INHIBITOR

lead_sponsor: Wyeth Research Division of Wyeth Pharmaceuticals Inc., Clinical Research and Development


title: A PARALLEL-GROUP, RANDOMIZED, DOUBLE-BLIND, MULTI-CENTER DOSE RESPONSE STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF- 00885706, A 5-HT4 RECEPTOR PARTIAL AGONIST, AS ADD-ON THERAPY TO ESOMEPRAZOLE FOR THE RELIEF OF SYMPTOMS IN SUBJECTS WITH GASTRO-ESOPHAGEAL REFLUX DISEASE (GERD) WHO HAVE A POOR RESPONSE TO PROTON PUMP INHIBITOR (PPI) TREATMENT

lead_sponsor: Pfizer Limited, Ramsgate Road, Sandwich, Kent, UK


title: A 12-week treatment, multi-center, randomized, double-blind, placebo controlled, parallel group study to assess the efficacy and safety of indacaterol (150 µg o.d.) in patients with chronic obstructive pulmonary disease.


title: Randomised, double-blind, parallel-group, placebo-controlled, duloxetine-referenced, fixed dose study comparing the efficacy and safety of Lu AA21004 in acute treatment of major depressive disorder in elderly patients

acronym: Not applicable

lead_sponsor: H. Lundbeck A/S


title: Randomized, controlled, double-blind multicenter safety study to evaluate the safety and immunogenicity of subcutaneous EPO HEXAL vs. ERYPO® in the treatment of anemia associated with chronic renal insufficiency in predialysis patients

lead_sponsor: HEXAL Biotech ForschungsGmbH


title: A Randomized Phase II Study of Fulvestrant in Combination with the dual mTOR Inhibitor AZD2014 or Everolimus or Fulvestrant alone in Estrogen Receptor-Positive Advanced or Metastatic Breast Cancer.

acronym: MANTA

lead_sponsor: Queen Mary, University of London


title: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-controlled Study of AG-120 in Previously-treated Subjects with Nonresectable or Metastatic Cholangiocarcinoma with an IDH1 Mutation

acronym: ClarIDHy

lead_sponsor: Agios Pharmaceuticals, Inc.


title: A TREATMENT PROTOCOL FOR PATIENTS CONTINUING FROM A PRIOR SU011248 PROTOCOL

lead_sponsor: Pfizer Inc.


title: Efficacy evaluation of DOTAREM®-enhanced MRA compared to GADOVIST®–enhanced MRA in the diagnosis of clinically significant abdominal or lower limb arterial diseases

lead_sponsor: GUERBET


title: Anastrozole monotherapy versus maximal oestrogen blockage with anastrozole and fulvestrant comination therapy: An open, randomised, comparative, phase III multicentre study in postmenopausal women with hormone receptor positive breast cancer in first relapse after primary treatment of localised tumour.

acronym: FACT

lead_sponsor: AstraZeneca AB


title: A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF FILIBUVIR PLUS PEGYLATED INTERFERON ALFA-2A AND RIBAVIRIN IN TREATMENT NAÏVE, HCV GENOTYPE 1 INFECTED SUBJECTS

lead_sponsor: Pfizer Inc, 235 East 42nd Street, New York, NY 10017


title:
A randomized  Discontinuation Study of Brivanib alaninate (BMS-582664) versus Placebo in Subjects with Advanced Tumors.
 Revised protocol 01 incorporating Amendment 02

lead_sponsor: Bristol Myers Squibb International Corporation


title: Randomized, Phase 2 Study of FOLFOX or FOLFIRI with AG-013736 or Bevacizumab in Patients with Metastatic Colorectal Cancer after Failure of an Irinotecan or Oxaliplatin-containing First-line Regimen

lead_sponsor: Pfizer Inc, 235 East 42nd Street, New York, NY 10017, USA


title: A Phase 3b,randomized,double-blind,placebo-controlled parallel-design study to evaluate the efficacy and safety of tadalafil coadministered with finasteride for  6 months in men with lower urinary tract symptoms(LUTS) and prostatic enlargement secondary to benign prostatic hyperplasia(BPH)

acronym: LVIW

lead_sponsor: Eli Lilly and Company Limited


title: A Multicentre, Randomised, Double Blind, Placebo controlled Phase IIb Study to compare the Efficacy and Safety of Two Dosing Regimens of Intravenous Infusions of CytoFab™ (AZD9773) in Adult Patients With Severe Sepsis and/or Septic Shock


title: An open label, multinational, multicenter study to evaluate the safety of HX575 recombinant human erythropoietin alfa

lead_sponsor: Hexal AG


title: A Single Arm Multicentre Phase II Study of Panitumumab in Combination with Irinotecan/5-Fluorouracil/Leucovorin in Patients with Metastatic Colorectal Cancer

lead_sponsor: Amgen Inc


title: A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel Group Study of the Efficacy and Safety of Intraprostatic Administration of BOTOX® 200 U (Botulinum  Toxin Type A) Purified Neurotoxin Complex to Treat Lower Urinary Tract Symptoms due to Benign Prostatic Hyperplasia

lead_sponsor: Allergan Limited


title: Effect of Passive Immunization on the Progression of Alzheimer’s Disease:  LY2062430 versus Placebo

lead_sponsor: Eli Lilly and Company


title: A phase III study of Pomalidomide and low dose Dexamethasone with or without Pembrolizumab (MK3475) in refractory or relapsed and refractory Multiple Myeloma (rrMM) (KEYNOTE 183)

acronym: A phase III study of Pomalidomide and Dexamethasone with or without Pembrolizumab in rrMM

lead_sponsor: Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.


title: A RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTRE PHASE IIB DOSE-FINDING STUDY OF M516102 IN THE TREATMENT OF PRURITUS ASSOCIATED WITH ATOPIC DERMATITIS.

lead_sponsor: Maruho Co., Ltd


title: A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF AL002 IN PARTICIPANTS WITH EARLY ALZHEIMER’S DISEASE

lead_sponsor: Alector Inc.


title: Randomised, double-blind, double-dummy, multicentre trial to evaluate the efficacy and safety of three different weekly dosages of calcifediol versus placebo in subjects with either vitamin D deficiency or insufficiency

acronym: WORFEROL

lead_sponsor: FAES FARMA S.A.


title: A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy

lead_sponsor: Incyte Corporation


title: A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION AND EXPANSION STUDY OF ENTRECTINIB (RXDX-101) IN PEDIATRICS AND YOUNG ADULTS WITH NO CURATIVE FIRST-LINE TREATMENT OPTION OR RECURRENT/REFRACTORY SOLID TUMORS AND PRIMARY CNS TUMORS

lead_sponsor: F. Hoffmann-La Roche Ltd


title: A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLEBLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-220 IN SUBJECTS WITH ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS

lead_sponsor: Celgene Corporation


title: Phase 3b, Randomized Trial of Revlimid® (Lenalidomide) Versus Placebo Maintenance Therapy Following Melphalan Prednisone Velcade® (Bortezomib) Induction Therapy in Newly Diagnosed Multiple Myeloma

acronym: ARUMM


title:
A Phase 2 Randomized Study of the Efficacy and Safety of Acalabrutinib with Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized with COVID-19

 Étude de phase 2 randomisée évaluant l’efficacité et la tolérance de l’acalabrutinib associé aux Meilleurs Soins de Support (Best Supportive Care - BSC) vs Meilleurs Soins de Support chez des patients hospitalisés infectés par le COVID-19

acronym: CALAVI

lead_sponsor: Acerta Pharma B.V.


title:
EPITOPE OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM CLINICAL BENEFIT AND SAFETY OF DBV712 IN PEANUT-ALLERGIC CHILDREN (EPOPEX)

 Étude d’extension en ouvert EPITOPE visant à évaluer le bénéfice clinique à long terme et la sécurité d’emploi du DBV712 chez des enfants allergiques à l’arachide (EPOPEX)

acronym: EPOPEX

lead_sponsor: DBV TECHNOLOGIES S.A.


title: A Pivotal, Multicenter, Blinded, Sham Procedure-Controlled Trial of Renal Denervation by the Peregrine System™ Kit, in Subjects with Hypertension.

acronym: The TARGET BP I Trial

lead_sponsor: Ablative Solutions, Inc


title:
A Multi-Center, Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of BMS-986165 in Subjects with Moderate-to-Severe Plaque Psoriasis

 Étude de phase 3 multicentrique, randomisée, en double aveugle, contrôlée par placebo et par traitement comparateur actif, visant à évaluer l’efficacité et la sécurité d’emploi de BMS-986165 chez des sujets atteints de psoriasis en plaques modéré à sévère

lead_sponsor: Bristol-Myers Squibb Company


title: A randomized, multicenter, parallel-group, Phase III study to compare the efficacy of arfolitixorin versus leucovorin in combination with 5 fluorouracil, oxaliplatin, and bevacizumab in patients with advanced colorectal cancer.

lead_sponsor: Isofol Medical AB


title: Aldose Reductase Inhibition for Stabilization of Exercise capacity in Heart Failure (ARISE-HF): A Multicenter, Randomized, Placebo-Controlled Study to Evaluate the Safety and Efficacy of AT-001 in Patients with Diabetic Cardiomyopathy / Stage B Heart Failure at High Risk of Progression to Overt Heart Failure (Stage C Heart Failure)

acronym: ARISE-HF

lead_sponsor: Applied Therapeutics Inc.


title: A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 1b/2a Study of WVE-003 Administered Intrathecally in Patients With Huntington’s Disease

lead_sponsor: Wave Life Sciences UK Limited


title: A Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial With an Open-Label Extension Phase of Perampanel as Adjunctive Treatment in Subjects at Least 2 years of Age With Inadequately Controlled Seizures Associated With Lennox-Gastaut Syndrome

lead_sponsor: Eisai Limited


title:
A Randomized, Double-blind, Placebo-Controlled, Active Comparator, Multicenter, Phase 3 Study of Brentuximab Vedotin or Placebo in Combination With Lenalidomide and Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)

 Étude randomisée, en double aveugle, contrôlée par placebo, avec comparateur actif, multicentrique, de phase 3 portant sur le brentuximab védotine ou un placebo en association avec du lénalidomide et du rituximab chez des patients atteints d’un lymphome diffus à grandes cellules B (LDGCB) en rechute ou réfractaire

lead_sponsor: Seattle Genetics, Inc.


title: A Phase 3 Randomized, Open-label Study to Evaluate the Efficacy and Safety of Olaparib Alone or in Combination With Bevacizumab Compared to Bevacizumab with 5-FU in Participants with Unresectable or Metastatic Colorectal Cancer who Have Not Progressed Following First-line Induction of FOLFOX With Bevacizumab (LYNK-003).

lead_sponsor: Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.,Inc


title:
PROLONGSTEM: HepaStem Long-Term Safety Registry Registry for patients who have been administered HepaStem

 PROLONGSTEM : Registre sur la sécurité à long terme d’HepaStem Registre pour les patients qui ont été perfusés avec HepaStem

lead_sponsor: Promethera Biosciences


title: A Phase 2 Dose Ranging Study to Evaluate the Efficacy and Safety of AMG 570 in Subjects With Active Systemic Lupus Erythematosus (SLE) With Inadequate Response to Standard of Care (SOC) Therapy

acronym: Safety and Efficacy of AMG 570 in Subjects With Active Systemic Lupus Erythematosus (SLE)

lead_sponsor: Amgen Inc


title: A Phase II Clinical Trial of Pembrolizumab as Monotherapy and in Combination with Cisplatin+5-Fluorouracil in Subjects with Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (KEYNOTE-059)

acronym: A Phase II Study of Pembrolizumab in Subjects with Gastric Cancer

lead_sponsor: Merck Sharp & Dohme Corp., a Subsidiary of Merck & Co., Inc.


title: A phase III study of Lenalidomide and low-dose Dexamethasone with or without Pembrolizumab (MK3475) in newly diagnosed and treatment naïve Multiple Myeloma (KEYNOTE 185).

acronym: Study of Lenalidomide and Dexamethasone with or without Pembrolizumab in Multiple Myeloma

lead_sponsor: Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.


title: A Phase 2, Open-label Study to Evaluate the Efficacy and Safety of KB195 in Subjects with a Urea Cycle Disorder with Inadequate Control on Standard of Care

lead_sponsor: Kaleido Biosciences


title: A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Apremilast in Children From 5 to Less Than 18 Years of Age With Active Juvenile Psoriatic Arthritis (PEAPOD)

lead_sponsor: Amgen Inc.


title: A Randomized Phase 3 Study of Sitravatinib in Combination with Nivolumab Versus Docetaxel in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer with Disease Progression On or After Platinum-Based Chemotherapy and Checkpoint Inhibitor Therapy (SAPPHIRE)

lead_sponsor: Mirati Therapeutics, Inc.


title:
A Multinational, Randomized, Double-blind, Parallel-group, Placebo-controlled Study to Investigate the Use of Benralizumab as a Treatment Option for Patients with Bullous Pemphigoid

 Étude internationale, randomisée, en double aveugle, en groupes parallèles et contrôlée par placebo, évaluant l’utilisation du benralizumab pour le traitement de patients atteints de pemphigoïde bulleuse

acronym: FJORD

lead_sponsor: AstraZeneca AB


title:
A phase Ib/II open-label, multi-center dose escalation study of JDQ443 in patients with advanced solid tumors harboring the KRAS G12C mutation

 Etude de phase Ib/II en ouvert, multicentrique, d’escalade de dose, évaluant le JDQ443 chez des patients atteints de tumeurs solides avancées présentant la mutation KRAS G12C

lead_sponsor: Novartis Pharma AG


title:
A phase 2 study of Belantamab Mafodotin in patients with relapsed or refractory AL amyloidosis

 Une étude de phase 2 de Belantamab Mafodotin chez des patients atteints d'Amylose de type AL, récidivante ou réfractaire

lead_sponsor: European Myeloma Network – EMN


title: Open-label Uncontrolled Trial to Evaluate Pharmacokinetics, Pharmacodynamics, Safety, and Activity of Efgartigimod in Children From 2 to Less Than 18 Years of Age With Generalized Myasthenia Gravis

acronym: ADAPT JR

lead_sponsor: argenx BV


title: A Phase 3, Double-Blind, Randomized, 8-Week, Vehicle-Controlled Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long Term Safety Extension Period in Adolescents and Adults With Atopic Dermatitis

acronym: Topical Ruxolitinib Evaluation in Atopic Dermatitis Study 1 (TRuE AD1)

lead_sponsor: Incyte Corporation


title: A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Effects of EDP-938 in Adult Hematopoietic Cell Transplant Recipients With Acute Respiratory Syncytial Virus Infection of the Upper Respiratory Tract

lead_sponsor: Enanta Pharmaceuticals, Inc.


title:
A randomised, double-blind, placebo-controlled, proof-of-concept, dose-ranging study of BI 655066 in patients with active psoriatic arthritis

 Etude randomisée en double aveugle, contrôlée versus placebo, de preuve de concept et de recherche de dose du BI 655066 chez des patients atteints de rhumatisme psoriasique actif

lead_sponsor: Boehringer Ingelheim France


title: A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study to Evaluate the Efficacy and Safety of E2609 in Subjects with Early Alzheimer’s Disease

lead_sponsor: Eisai Ltd.


title: A Phase 2, Randomized Study of VELCADE® (bortezomib), Dexamethasone, and Thalidomide Versus VELCADE® (bortezomib), Dexamethasone, Thalidomide, and Cyclophosphamide in Subjects With Previously Untreated Multiple Myeloma Who are Candidates for Autologous Transplantation.

lead_sponsor: Janssen-Cilag International, N.V.Turnhoutseweg 30, 2340 Beerse, Belgium


title: A Multicenter, Randomized, Double-Blind, Double-Dummy, Parallel-Group Study Evaluating the Effects of 2 Different Regimens of Montelukast (Daily Dosing and Intermittent, Episode-Driven Dosing) Compared With Placebo in the Treatment of Episodic Asthma in Children Aged 6 Months to 5 Years

acronym: Intermittent and Daily Treatment for Episodic Asthma (IDEA)

lead_sponsor: Laboratoires Merck Sharp & Dohme - Chibret


title: A Dose-Ranging Study of the Effects of SCH 527123 in Subjects With Moderate to Severe COPD

lead_sponsor: Schering-Plough Research Institute


title: A Randomized, Open-label, Multi-center Trial Investigating Zalutumumab, a Human Monoclonal Anti-EGF receptor Antibody, in Combination with Chemo-Radiation in Stage IIIA-IIIB Non Small Cell Lung Cancer Patients

acronym: Zalutumumab in Combination with Chemo-Radiation in NSCLC

lead_sponsor: Genmab A/S


title: An observational, safety follow-up extension to studies 2203 and 2203E1 to assess the safety of AAE581 in postmenopausal women with osteopenia/osteoporosis

lead_sponsor: Novartis Pharma Services AG


title: A randomized phase II trial of ridaforolimus (AP23573; MK-8669) compared to progestin or chemotherapy in female adult patients with advanced endometrial carcinoma

lead_sponsor: ARIAD Pharmaceuticals, Inc.


title: Cetrorelix pamoate (AEZS-102) in patients with symptomatic BPH: a double-blind placebo-controlled efficacy study

lead_sponsor: Aeterna Zentaris GmbH


title: A multi-centre, multinational, open- label study to evaluate the long-term safety, tolerability and efficacy of NS-304 in the treatment of pulmonary arterial hypertension in subjects aged 18 years and over (open-extension study to NS-304/-02)

lead_sponsor: Nippon Shinyaku Co., Ltd.


title: Impact of the V0034CR 01B emollient on atopic dermatitis symptoms in children. A randomised, placebo-controlled, parallel-groups, double-blind study

lead_sponsor: Pierre Fabre Médicament


title: A Double-Blind, Randomised, Placebo-Controlled, Parallel-Group, 12-Week Study of Pitavastatin in High-Risk Hyperlipidaemia in Childhood P/266/2011, P267/2011, P268/2011

acronym: PASCAL 401

lead_sponsor: Kowa Research Europe, Ltd.


title: A randomised, double-blind, placebo-controlled, multi-national, Phase III trial to assess the efficacy and safety of 300 IR sublingual immunotherapy (SLIT) administered as allergen-based tablets once daily to adolescents and children above the age of 5 years, suffering from house dust mite allergic rhinitis

lead_sponsor: Stallergenes S.A.


title: A Randomised, Double-Blind, Placebo-Controlled, Multicentre Phase II Study to Compare the Efficacy, Safety and Tolerability of Olaparib Versus Placebo When Given in Addition to Abiraterone Treatment in Patients With Metastatic Castrate-Resistant Prostate Cancer Who Have Received Prior Chemotherapy Containing Docetaxel

lead_sponsor: AstraZeneca AB


title: A Randomised, Multicentre, Open Label, Phase II study of Prophylactic Octreotide to Prevent or Reduce the Frequency and Severity of Diarrhoea in Subjects Receiving Lapatinib with Capecitabine for the Treatment of Metastatic Breast Cancer.

lead_sponsor: GlaxoSmithKline research & Development


title: A Safety and Efficacy Study of SCH 503034 in Previously Untreated Subjects With Chronic Hepatitis C Infected With Genotype 1


title: An Open-Label Extension Study of the Long-Term Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (IPF) Who Complete the CAPACITY Studies

acronym: Open-Label Extension of Pirfenidone CAPACITY Studies

lead_sponsor: InterMune, Inc.


title: NON-INFERIORITY STUDY OF A METRONIDAZOLE 0.75% CREAM VERSUS REFERENCE THERAPY IN THE LOCAL TREATMENT OF PAPULOPUSTULAR ROSACEA.

lead_sponsor: Pierre Fabre Dermatologie represented by Institut de Recherche Pierre Fabre


title: Vicriviroc in Combination Treatment with an Optimized ART Regimen in HIV-Infected Treatment-Experienced Subjects (VICTOR-E4)


title: A PHASE 2B MULTICENTER, RANDOMIZED, COMPARATIVE TRIAL OF UK-453,061 VERSUS ETRAVIRINE IN COMBINATION WITH DARUNAVIR/RITONAVIR AND A NUCLEOTIDE/NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR FOR THE TREATMENT OF ANTIRETROVIRAL EXPERIENCED HIV-1 INFECTED SUBJECTS WITH EVIDENCE OF NNRTI RESISTANT HIV-1

lead_sponsor: Pfizer Inc


title: Efficacy and safety of ASF 1057 cream 0.5% in the treatment of seborrhoeic dermatitis: A phase III randomised, double-blind, vehicle-  and placebo controlled, parallel groups, multi-centre trial.

lead_sponsor: Astion Pharma A/S


title: A Randomized, Double-Blind, Phase III Trial of STA-4783 in Combination with Paclitaxel versus Paclitaxel Alone for Treatment of Chemotherapy-Naïve Subjects with Stage IV Metastatic Melanoma

lead_sponsor: Synta Pharmaceuticals Corp.


title: An open-label, single-arm, multi-center phase 2 trial with ofatumumab in patients with relapsed Diffuse Large B-Cell Lymphoma (DLBCL) ineligible for transplant or relapsed after autologous transplant

acronym: Ofatumumab in patients with relapsed DLBCL ineligible for or relapsed after transplant


title: Phase II open label study to evaluate the safety of a second i.p. infusion cycle of catumaxomab in patients with malignant ascites due to carcinoma, requiring their first therapeutic puncture after treatment in the CASIMAS study (IP-CAT-AC-03)

acronym: SECIMAS

lead_sponsor: Fresenius Biotech GmbH


title: A Double-blind, Placebo-controlled, Multicenter Study of the Efficacy and Safety of Adalimumab in Pediatric Subjects with Enthesitis Related Arthritis

lead_sponsor: Abbott GmbH & Co. KG (Abbott)


title: A Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Evaluate the Long-term Efficacy, Safety and Tolerability of Extended-Release (ER) Niacin and Laropiprant (ERN/LRPT) in Patients with Dyslipidemia

lead_sponsor: Merck & Co., Inc.


title: A multicenter, randomized, double blind (double dummy), active-comparator controlled study to compare the efficacy, safety and tolerability of taspoglutide versus pioglitazone in type 2 diabetes patients inadequately controlled with sulfonylurea (SU) monotherapy or metformin plus sulfonylurea combination therapy.

acronym: EMERGE 6

lead_sponsor: F. Hoffmann-La Roche Ltd


title: A Randomized, Open label, Multicenter, Dose and Duration Finding Study to Evaluate the Sustained Virologic Response of the HCV Protease Inhibitor Danoprevir (RO5190591) Boosted with Low Dose Ritonavir (danoprevir/r) in Combination with Pegasys® and Copegus® versus Pegasys® and Copegus® alone in Treatment-Naive Patients with Chronic Hepatitis C Genotype 1 or 4 Virus Infection

lead_sponsor: F.Hoffmann-La Roche


title: A multicenter, randomized, double-blind, 8 week study to evaluate the dose response, efficacy and safety of aliskiren in pediatric hypertensive patients 6-17 years of age.

lead_sponsor: Novartis Pharma Services AG


title: Prospective randomised phase II trial of oral vinorelbine and cisplatin or pemetrexed and cisplatin in first line Metastatic or Locally Advanced Non-Small-Cell Lung Cancer patients with non-squamous histological type.

lead_sponsor: PIERRE FABRE MEDICAMENT


title: A randomized, observer-blind, active-controlled phase III study to demonstrate the superior efficacy of GSK Biologicals’ adjuvanted influenza candidate vaccine [GSK2186877A], administered intramuscularly in elderly aged 65 years or above, as compared to Fluarix™.

acronym: FLU NG-006 PRI

lead_sponsor: GlaxoSmithKline Biologicals


title:
A Randomized, Open-Label Study to Evaluate the Safety and Efficacy of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 Coadministered
 with Ribavirin (RBV) in Adults with Genotype 1 Chronic Hepatitis C Virus (HCV) Infection and Cirrhosis (TURQUOISE-II)

lead_sponsor: Abbott GmbH & Co. KG


title: A multicenter, double-blind, placebo-controlled, randomised, parallel-group phase 3 study to evaluate the safety and efficacy of masitinib in patients with mild to moderate Alzheimer’s disease

lead_sponsor: AB Science

status: Prohibited by CA


title: PiSARRO: p53 Suppressor Activation in Recurrent High Grade Serous Ovarian Cancer, a Phase Ib/II Study of Systemic Carboplatin Combination Chemotherapy With or Without APR-246

acronym: PiSARRO

lead_sponsor: Aprea AB


title: A Phase III, Open Label, Randomized Study of AZD9291 versus Platinum-Based Doublet Chemotherapy for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer whose Disease has Progressed with Previous Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and whose Tumours harbour a T790M mutation within the Epidermal Growth Factor Receptor Gene (AURA3)

lead_sponsor: AstraZeneca AB


title: Phase III confirmatory efficacy and safety trial of remimazolam (CNS7056) compared with propofol for intravenous anaesthesia during elective surgery

lead_sponsor: PAION UK Limited


title:
A PHASE 2/3, MULTICENTER, MULTINATIONAL, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ALXN1101 IN NEONATES WITH MOLYBDENUM COFACTOR DEFICIENCY (MOCD) TYPE A

 Etude en ouvert de phase II/III, multicentrique et internationale, visant à évaluer l'efficacité et la sécurité d'emploi de l'ALXN1101 chez des nouveau-nés présentant un déficit en cofacteur molybdène (MoCoD) de type A

lead_sponsor: Alexion Pharma GmbH


title: A phase I pharmacokinetic and safety study of tocilizumab (TCZ) in patients less than 2 years old with active systemic juvenile idiopathic arthritis (sJIA)


title: A Ten-Week, Multicenter, Randomized, Double-Blind, Placebo and Active-Controlled, Parallel-Group, Flexible-Dose Study Evaluating the Efficacy, Safety, and Tolerability of GSK372475 (1.5 mg/day to 2.0 mg/day) or Extended Release Venlafaxine XR (150 mg/day to 225 mg/day) Compared to Placebo in Adult Subjects Diagnosed with Major Depressive Disorder.

lead_sponsor: GlaxoSmithKline Research & Development


title: A randomised, double-blind, placebo-controlled, multi-national, multi-centre, Phase III study to assess the long term efficacy, carry-over effect and safety of two dosing regimens of 300 IR sublingual immunotherapy (SLIT) administered as allergen-based tablets once daily to patients suffering from grass pollen rhinoconjunctivitis

lead_sponsor: Stallergenes S.A.


title: A Multi-center, Open-label, 5-Part Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Aprepitant and Fosaprepitant Dimeglumine in Pediatric Patients Receiving Emetogenic Chemotherapy

lead_sponsor: Laboratoires Merck Sharp & Dhome-Chibret


title: The H10 EORTC/GELA randomized intergroup trial on early FDG-PET scan guided treatment adaptation versus standard combined modality treatment in patients with supradiaphragmatic stage I/II Hodgkin's lymphoma

lead_sponsor: ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)